Symbiotec Pharma — 360° view

Symbiotec Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹280 crore and net profit of ₹52 crore for the September 2026 quarter.

Symbiotec Pharma (NSE: SYMBIOTEC) closed at ₹1,598.60 on 20 Nov 2026. Its market capitalisation is ₹10,272 crore and it trades at 69.5 times earnings.

Share price
₹1,598.60 (20 Nov 2026)
Market cap
₹10,272 Cr (20 Nov 2026)
P/E
69.49 (20 Nov 2026)
Revenue
₹280 Cr (September 2026 quarter)
Net profit
₹52 Cr (September 2026 quarter)
ROCE
13.0% (FY26)
ROE
11.7% (FY26)
Book value
₹212 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,664.90 / ₹985.50 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SYMBIOTEC

Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.